2gvg: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2gvg" size="450" color="white" frame="true" align="right" spinBox="true" caption="2gvg, resolution 2.2Å" /> '''Crystal Structure of...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2gvg.gif|left|200px]]<br />
[[Image:2gvg.gif|left|200px]]<br /><applet load="2gvg" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2gvg" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2gvg, resolution 2.2&Aring;" />
caption="2gvg, resolution 2.2&Aring;" />
'''Crystal Structure of human NMPRTase and its complex with NMN'''<br />
'''Crystal Structure of human NMPRTase and its complex with NMN'''<br />


==Overview==
==Overview==
Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in, the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of, NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in, tumors. We have determined the crystal structures at up to 2.1-A, resolution of human and murine NMPRTase, alone and in complex with the, reaction product nicotinamide mononucleotide or the inhibitor FK866. The, structures suggest that Asp219 is a determinant of substrate specificity, of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound, in a tunnel at the interface of the NMPRTase dimer, and mutations in this, binding site can abolish the inhibition by FK866. Contrary to current, knowledge, the structures show that FK866 should compete directly with the, nicotinamide substrate. Our structural and biochemical studies provide a, starting point for the development of new anticancer agents.
Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors. We have determined the crystal structures at up to 2.1-A resolution of human and murine NMPRTase, alone and in complex with the reaction product nicotinamide mononucleotide or the inhibitor FK866. The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866. Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate. Our structural and biochemical studies provide a starting point for the development of new anticancer agents.


==About this Structure==
==About this Structure==
2GVG is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PO4 and NMN as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Nicotinamide_phosphoribosyltransferase Nicotinamide phosphoribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.12 2.4.2.12] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2GVG OCA].  
2GVG is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PO4:'>PO4</scene> and <scene name='pdbligand=NMN:'>NMN</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Nicotinamide_phosphoribosyltransferase Nicotinamide phosphoribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.12 2.4.2.12] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2GVG OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Nicotinamide phosphoribosyltransferase]]
[[Category: Nicotinamide phosphoribosyltransferase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Khan, J.A.]]
[[Category: Khan, J A.]]
[[Category: Tao, X.]]
[[Category: Tao, X.]]
[[Category: Tong, L.]]
[[Category: Tong, L.]]
Line 26: Line 25:
[[Category: visfatin]]
[[Category: visfatin]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:23:06 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:35:49 2008''